Volume 2 - Issue 2, Winter 2008 - Industry News: An Overview of the Latest Updates from Technology & Industry
CV Therapeutics Announces License Agreement
Ranexa will be launched to specialists and primary care physicians. It is approved for use in Europe as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to firstline antianginal therapies.
Print as PDF